Clinical trials: Ulcerative Colitis in Remission
Colitis, Ulcerative, Recurrence
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs.
- Trial name
- NCT00746447
- Testing
- mesalamine granules
- Where
- Germany
- Volunteers
- 648 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00767728
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis in Remission
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase
To demonstrate that import Mesalazine (ASACOL®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool), in patients with Ulcerative Colitis in remission…
- Trial name
- NCT01257399
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
The purpose of this study is to determine if PF-06687234 is effective and safe as add-on therapy to infliximab in subjects with active ulcerative colitis who are not in remission.
- Trial name
- NCT03269695
- Testing
- PF-06687234
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active…
- Trial name
- HIBISCUS II (NCT02171429)
- Testing
- Adalimumab, Etrolizumab
- Where
- 90 sites in United States, Argentina and 17 more
- Volunteers
- 358 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a…
- Trial name
- NCT00209287
- Testing
- Observe patients with inactive ulcerative colitis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Ferring Pharmaceuticals